Cly-Del Manufacturing Co. in Waterbury has acquired a Naugatuck-based tool company, according to an announcement. Cly-Del recently purchased Semco Tool & Manufacturing Co. Inc., which produces custom ...
Phase 1 proof-of-concept study of CLY-124 in Sickle Cell Disease expected in Q4 2026 In vivo preclinical data assessing new compounds vs. standard of care in gold-standard, translatable myelofibrosis ...
SOMERVILLE, Mass., June 26, 2025 /PRNewswire/ -- Cellarity, a biotechnology company developing Cell State-Correcting therapies through integrated multi-omics and AI modeling, today announced that the ...
Cellarity has dosed the first subject in a Phase I study of oral medication, CLY-124, to treat sickle cell disease (SCD). This development follows the US Food and Drug Administration's (FDA) clearance ...
The MarketWatch News Department was not involved in the creation of this content. Initiation follows successful IND clearance based on preclinical data package indicating robust increase in fetal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback